R-CHOP economically dominant over CHOP in DLBCL

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.544, 2008-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

R-CHOP economically dominant over CHOP in DLBCL

Inpharma, Vol. 1, Iss. 1619, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 110-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP

Current Cancer Drug Targets, Vol. 14, Iss. 7, 2014-09 ,pp. : 659-670

Bentham Science Publishers

Access to resources Recommend Favorite

NHL gets the CHOP with rituximab

Inpharma, Vol. 1, Iss. 1226, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

PCI "economically dominant" over CABG in high-risk patients

Inpharma, Vol. 1, Iss. 1566, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite